Lab monitoring, in plain words
GLP-1 Blood Work: What to Check, What to Skip, and When to See a Doctor
This guide to GLP-1 blood work is for people taking semaglutide, tirzepatide or retatrutide. It isn't about GLP-1 hormone or drug-level tests. It covers what the four FDA labels and current guidelines say about each marker, what we suggest, and which symptoms need a doctor today instead of a lab order.
Key Takeaways
- No label or guideline sets one lab schedule for everyone on a GLP-1.
- The firmest label links: kidney function when vomiting or diarrhea could dehydrate you, blood glucose (Wegovy and Zepbound labels) with diabetes, and narrow-range pills such as warfarin.
- Severe stomach pain that won't go away is a reason to get seen today, not to order a panel.
- A baseline before your first dose is our suggestion: later numbers need something to be compared with.
Retatrutide is investigational
Retatrutide is not FDA approved and has no prescribing information. Facts about it here come from its Phase 2 trial publication and ClinicalTrials.gov results. Otherwise, approved GLP-1 labels are the nearest reference, by extrapolation.
Before You Order: Symptoms That Need a Doctor, Not a Panel
Lab work is for people who feel fine. With any symptom below, a home panel is the wrong tool.
Severe stomach pain that won't go away: get seen today.
The Medication Guides for Wegovy, Ozempic, Zepbound and Mounjaro tell you to stop using the medicine and call your healthcare provider right away if you have severe pain in your stomach area that will not go away, with or without vomiting. The pain can spread to your back. This is the pancreatitis warning. If you cannot reach anyone, go to urgent care or an emergency room.
Also tell a clinician promptly about:
- Gallbladder signs: upper stomach pain, fever, yellowing of skin or eyes, clay-colored stools (Medication Guides).
- Dehydration: nausea, vomiting or diarrhea that does not go away, which the guides link to kidney problems.
- Thyroid signs: a neck lump, trouble swallowing, shortness of breath or lasting hoarseness (boxed warning).
- Heart: palpitations or a racing heartbeat at rest (Wegovy label).
- Low blood sugar if you also take insulin or a sulfonylurea.
Know When Your Dose Changes Land
Side effects can be dose-related. Map your dose steps first.
What to Order for Your GLP-1 Blood Work (and What to Skip)
No label sets a required lab panel. In the table, label means FDA prescribing information gives direction on whether to test, guideline means ADA or a society advisory does, and our suggestion is GLP3Planner's take, not an official recommendation.
| Test | Evidence | Our take |
|---|---|---|
| Metabolic panel (creatinine, eGFR, BUN, electrolytes) | Label: renal function if dehydrated | Order. Worth a baseline. |
| Fasting blood glucose | Label (Wegovy, Zepbound), with diabetes | Order. Without diabetes, it tracks the benefit. |
| A1C | Guideline (ADA), with diabetes | Order if you have diabetes; otherwise optional. |
| Lipid panel | Our suggestion | Optional benefit tracking. |
| Liver enzymes (ALT, AST, ALP, bilirubin) | Our suggestion | Optional general baseline. |
| Lipase and amylase | Our suggestion | Optional baseline only. Hard to read later without symptoms. |
| Iron, B12, vitamin D | Guideline (expert opinion) | Optional (ferritin is a common iron test) if you eat little or lose weight fast. |
| TSH | Our suggestion (on levothyroxine? see the oral-medicines note) | Optional general health. Not a cancer screen. |
| Calcitonin | Label: routine monitoring of uncertain value | Skip as a screening test. |
| Resting heart rate | Label (Wegovy only) | Measure at home. No lab needed. |
Pancreas and thyroid tags mean a symptom watch; gallbladder means a clinician workup.
Bring results to a clinician. An out-of-range value without symptoms is a question, not a diagnosis.
You can order many of these tests yourself from a direct-to-consumer lab without a doctor's visit, though some states limit this. Check the lab's test list against the table first.
Kidney and Pancreas: What the Labels Actually Ask For
Kidney
All four labels carry an acute kidney injury warning, tied mostly to dehydration from nausea, vomiting or diarrhea, and some cases needed dialysis. The labels tell prescribers to monitor renal function in people whose side effects could cause dehydration, especially at the start and after dose increases. Creatinine, eGFR, BUN and electrolytes are our list of what a kidney panel measures; the labels just say renal function. For keeping fluids up, see semaglutide nausea management and retatrutide nausea management.
Pancreas
The pancreatitis warning tells prescribers to watch closely for symptoms after starting treatment and to stop the medicine if pancreatitis is suspected. None of the four labels asks for routine lipase or amylase tests. Those enzymes appear only in each label's clinical-trial lab data, where average levels rose.
| Label | Mean lipase rise | Mean amylase rise |
|---|---|---|
| Ozempic | 22% | 13% |
| Wegovy | 39% | 15% to 16% |
| Zepbound | 28% to 35% | 20% to 25% |
| Mounjaro | 31% to 42% | 33% to 38% |
Trial populations differ, so these figures do not compare one brand against another.
The Wegovy, Zepbound and Mounjaro labels add that the clinical significance of these rises is unknown without other signs of pancreatitis. The Ozempic label does not include that sentence. That's why we suggest a lipase value before your first dose, so a later one has context. This is GLP3Planner's reasoning, not an FDA or ADA recommendation. ADA 2026 advises against starting these medicines in people at high risk of pancreatitis, and says incretin medicines should be avoided after a history of pancreatitis.
Retatrutide: one small Phase 2 obesity trial's posted ClinicalTrials.gov results list reported adverse events, not measured lab values: serious acute pancreatitis and serious acute kidney injury in 1 of 267 retatrutide participants each, versus 0 of 70 on placebo, and increased lipase in 15 of 267 versus 2 of 70.
Gallbladder, Liver, Blood Sugar and Lipids
Gallbladder and liver
All four labels report more gallbladder events, such as gallstones or gallbladder inflammation, than placebo. In Wegovy's adult weight-reduction trials, gallstones affected 1.6% on the injection versus 0.7% on placebo (2.5% versus 1% for the tablet), and weight loss alone did not explain the gap. When gallbladder disease is suspected, the labels call for gallbladder studies and clinical follow-up: a workup a clinician directs, not a routine panel you order ahead of time. Liver tests can be part of that workup.
No label asks for routine liver tests; ALT, AST and bilirubin appear only in Wegovy's trial data. A liver panel is a reasonable general-health baseline, nothing more.
Blood sugar
Low blood sugar is the safety issue. All four labels warn that the risk rises when the medicine is combined with insulin or a sulfonylurea, and that your prescriber may need to lower the dose of those drugs. The Wegovy and Zepbound labels tell people with diabetes to monitor blood glucose before starting and during treatment. For people with diabetes, ADA 2026 advises assessing glycemic status at least twice a year, and about every 3 months after a treatment change. Without diabetes, A1C and fasting glucose track the benefit; they are not a safety requirement.
Lipids
No label asks for lipid monitoring. ADA 2026 notes that in people with type 2 diabetes and overweight or obesity who are not at goal, modest sustained weight loss of 5% to 7% improves glycemia, blood pressure and lipids.
Thyroid: Why a TSH Test Is Not a Cancer Screen
The boxed warning on all four labels concerns thyroid C-cell tumors seen in rodents. Whether these medicines cause medullary thyroid carcinoma (MTC) in humans is unknown. They are contraindicated if you or a family member has had MTC, or if you have multiple endocrine neoplasia type 2 (MEN 2).
The labels also say routine calcitonin monitoring or thyroid ultrasound is of uncertain value for catching MTC early and may lead to unnecessary procedures. A high calcitonin measured by a doctor needs further evaluation, but don't buy one as screening.
The American Thyroid Association guideline describes MTC as arising from C-cells, with calcitonin and CEA as its tumor markers. TSH reflects thyroid hormone balance, a separate system, so a normal TSH tells you nothing about MTC. It's still a fair general-health check. For MTC, family history and symptoms are what count.
Nutrition Labs and Resting Heart Rate
Nutrition (weaker evidence, optional tests)
No FDA label names a nutrient test. ADA 2026 recommends monitoring nutrition during intentional weight loss (graded as expert opinion) and says people losing more than 20% of body weight, or more than 4% a month, should be screened for micronutrient deficiencies. It adds that there are no universal recommendations for how often. A 2025 joint advisory from four medical and nutrition societies (ACLM, ASN, OMA, TOS) suggests testing before therapy for people with risk factors such as a past deficiency, and re-checking nutrient levels during therapy. Both list iron, B12 and vitamin D among nutrients of concern; neither names a complete blood count.
Testing matters most when you eat little, lose weight fast, or notice fatigue or shedding (see hair loss on retatrutide).
Heart rate
The Wegovy label reports average rises of 1 to 4 beats per minute and is the only one of the four that tells prescribers to monitor heart rate and to stop treatment for a sustained rise. The other three report rises in trial data only. The retatrutide Phase 2 paper reports dose-dependent heart-rate increases that peaked at 24 weeks and then declined. Our suggestion: take a few resting readings before your first dose, and report palpitations or a racing heartbeat at rest.
When to Check: No Label or Guideline Sets a Lab Schedule
None of the labels or guidelines we cite gives one lab schedule for everyone. ADA 2026 advises clinicians to assess obesity medicines for safety and effectiveness at least monthly for the first 3 months, then at least quarterly, but ties no labs to those visits. For labs:
| Marker | Timing the source supports |
|---|---|
| Kidney | Dose starts and increases, when side effects could dehydrate you (labels) |
| Blood sugar, with diabetes | Before starting and during treatment (Wegovy, Zepbound); glycemic checks at least twice a year, about every 3 months after a change (ADA) |
| Micronutrients | No universal interval; screen after large or fast weight loss (ADA) |
| Pancreas, liver, lipids, thyroid | No interval stated |
Our suggestion: get a baseline before your first dose. Recheck when symptoms appear, when a dose increase brings vomiting or diarrhea, and on whatever cadence your clinician sets. A lower dose is no reason to skip the symptom watch; see microdosing side effects.
If you take other oral medicines
These medicines slow stomach emptying, which can affect pill absorption. In a Wegovy label study, the semaglutide tablet raised levothyroxine exposure by 33%, and the label suggests more clinical or lab monitoring for oral drugs with a narrow therapeutic index. The Zepbound and Mounjaro labels say to monitor people on such drugs, warfarin for example, and ADA 2026 repeats this for tirzepatide. The Ozempic label urges caution. If you take such a drug, ask its prescriber about closer monitoring.
Frequently Asked Questions
What labs should be checked on a GLP-1?
No label sets a required panel. All four labels tell prescribers to monitor kidney function when vomiting or diarrhea could dehydrate you. Wegovy and Zepbound add blood glucose if you have diabetes, and three labels flag narrow-range pills such as warfarin. A baseline of kidney, liver, blood sugar and lipid tests gives later results context.
How often should I get labs on a GLP-1?
No source we reviewed sets one lab schedule for everyone. Kidney checks tie to dose increases and dehydrating side effects. ADA advises reviewing obesity medicines at least monthly for 3 months, then quarterly, without naming labs. With diabetes, it advises glycemic checks at least twice a year, about every 3 months after a change.
Will a GLP-1 show up on a blood test?
The labs in this guide show how your body is responding, not how much medicine you took. We found no use of a drug blood level to guide care in the four FDA labels or the guidelines we cite, and a GLP-1 hormone test is not part of their monitoring.
Does a high lipase mean pancreatitis?
Not by itself. Average lipase rose by about 22% to 42% in the four labels' trial data, and the Wegovy, Zepbound and Mounjaro labels call the significance of a rise unknown without other signs of pancreatitis. The warning sign is severe stomach pain that won't go away.
Should I get a calcitonin or thyroid test on a GLP-1?
The labels say routine calcitonin monitoring is of uncertain value for early detection of medullary thyroid cancer and may lead to unnecessary procedures. TSH checks thyroid hormone balance, not this cancer. What matters is family history before starting and reporting a neck lump, hoarseness or trouble swallowing.
Is there a lab schedule for retatrutide?
No. Retatrutide is investigational, has no FDA label, and the published trials give no consumer monitoring schedule. Trial participants were monitored under a study protocol; that is not a consumer schedule. The approved GLP-1 labels are the nearest reference, and only that.
Bring Your Dose History to Your Clinician
References
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, Prescribing Information. DailyMed, effective 18 June 2026. [DailyMed]
- Novo Nordisk. OZEMPIC (semaglutide) injection, Prescribing Information. DailyMed, effective 1 June 2026. [DailyMed]
- Eli Lilly. ZEPBOUND (tirzepatide), Prescribing Information. DailyMed, effective 28 August 2026. [DailyMed]
- Eli Lilly. MOUNJARO (tirzepatide), Prescribing Information. DailyMed, effective 27 August 2026. [DailyMed]
- American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026. Diabetes Care. 2026;49(Suppl 1):S166-S182. [PMC]
- American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes–2026. Diabetes Care. 2026;49(Suppl 1):S132-S149. [PMC]
- American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes–2026. Diabetes Care. 2026;49(Suppl 1):S183-S215. [PMC]
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. Obesity. 2025;33(8):1475-1503. [PMC]
- Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. [PMC]
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed]
- ClinicalTrials.gov. A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760), posted results. [ClinicalTrials.gov]
Medical Disclaimer
This article is for informational purposes only and is not medical advice. Do not change any medication based on a lab result without a qualified healthcare provider.